Overview

Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma

Status:
RECRUITING
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma (CCA) at 12 months after surgery.
Phase:
PHASE2
Details
Lead Sponsor:
National Cancer Institute, Naples
Treatments:
Cisplatin
durvalumab
Gemcitabine